Induced Pluripotent Stem Cells: History and A Look Back
Explore the fascinating history of induced pluripotent stem cells, from early research milestones to recent advancements in cellular reprogramming techniques.
REPROCELL Expands Clinical iPSC and Stem Cell Solutions in China Through Strategic Collaboration with WEIPU Biotechnology
Yokohama, Japan / Suzhou, China – July 27, 2026 – REPROCELL Inc., a global provider of clinical-grade iPSC technologies and regenerative medicine solutions, today announced a strategic collaboration with WEIPU Biotechnology Co., Ltd., a biotechnology company based in Suzhou, China, to support cell therapy developers in China with access to high-quality clinical starting materials and…
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)
JAPAN, June 24, 2026 – REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in patients with…
AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy
Induced pluripotent stem cells (iPSCs) are rapidly advancing regenerative medicine and cell therapy because they can differentiate into multiple human cell types. However, immune rejection remains a major barrier to developing scalable allogeneic cell therapies. In a recent webinar, Dr. Luke Ren from REPROCELL presented how the company is using StemEdit, its advanced gene editing…
What Are Off-Target Effects in Cellular Gene Editing? Risks, Detection, and Solutions
What Are Off-target Effects in Gene Editing? Off-target effects in gene editing refer to unintended genetic modifications occurring at genomic loci other than the intended target site. In CRISPR-based gene editing systems, these arise because the guide RNA (gRNA), which directs the system to the target DNA sequence, can also bind to DNA sequences with…
Key Steps in Custom DNA Oligonucleotide Synthesis
What Is Custom DNA Oligonucleotide Synthesis? Custom DNA oligonucleotide synthesis is the chemical process of building short, single-stranded DNA sequences—called oligonucleotides or “oligos”—in a controlled, laboratory setting. These synthetic DNA molecules are indispensable tools in modern molecular biology, genomics, diagnostics, and therapeutic development. Whether you are designing primers for PCR amplification, probes for next-generation sequencing…
Bioserve – A REPROCELL Company Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services Beltsville, MD, USA / Yokohama, Japan – 3rd March 2026 Bioserve – A REPROCELL Company proudly announces the launch of US FDA-compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing services for human induced pluripotent stem cells (iPSCs), now available to support global…
Major Global News & Breakthroughs in Stem Cell Research
Stem cell research has entered a decisive translational era. Breakthroughs in induced pluripotent stem cell (iPSC) technology and precision gene editing are rapidly converting experimental concepts into clinically validated therapies. What were once proof-of-concept studies are now progressing through late-stage clinical trials and, in some cases, delivering first-in-human successes. These advances are unlocking new therapeutic frontiers…
Bioserve – A REPROCELL COMPANY Launches StemEdit: Clinical Gene Editing Services and New iPSC Lines Using AI-Designed Editing System
January 28th, 2026 – REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEdit encompasses REPROCELL’s proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL’s StemRNA™ Clinical…